Zocilurtatug Pelitecan Displays Meaningful Responses in Pretreated epNECs
Treatment with zocilurtatug pelitecan (ZL-1310) conferred clinically meaningful responses among patients with extrapulmonary neuroendocrine carcinomas (epNECs), according to findings from the open‑label phase 1b/2 ZL-1310‑002 trial (NCT06885281).
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management